EPCLUSA - VELPATASVIR 100MG /SOFOSBUVIR 400MG 28 TAB

EPCLUSA (VELPATASVIR 100MG/SOFOSBUVIR 400MG) 28 TABLETS

Product Description:
EPCLUSA is a prescription medication used to treat adults with chronic hepatitis C virus (HCV) genotype 1-6 infection. This single-tablet regimen combines 100mg of velpatasvir and 400mg of sofosbuvir, two antiviral medications that work in concert to inhibit HCV replication. EPCLUSA offers a ribavirin-free treatment option, suitable for use in a broad range of HCV patients, including those with compensated cirrhosis.

Technician Specifications:
- Active Ingredients: Velpatasvir 100mg, Sofosbuvir 400mg
- Formulation: Fixed-dose combination tablet
- Package Size: 28 tablets per bottle
- Dosage: One tablet taken orally once daily with or without food
- Treatment Duration: Typically 12 weeks, may vary based on patient's clinical status
- Storage: Store at room temperature away from moisture and heat

Common Applications/User Groups:
- Adults with chronic HCV genotypes 1-6
- Patients without cirrhosis or with compensated cirrhosis
- Suitable for patients who are HCV treatment-naïve or treatment-experienced

Overview of Gilead Sciences:
Gilead Sciences is a biopharmaceutical company that has established itself as a leader in the development of antiviral drugs, particularly in the treatment of HCV. With a commitment to advancing healthcare and an extensive research and development program, Gilead has brought to market several highly effective HCV therapies. Their authority in the product category is underscored by a robust portfolio of HCV treatments that have transformed the standard of care, offering cure rates exceeding 90% for many patient populations. Gilead's dedication to innovation, patient access, and support programs makes them a trusted supplier in the fight against chronic HCV infection.